Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. Please see our prior announcement for a summary of the transaction terms.
VTAMA(R) (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque psoriasis in adults with no safety label warnings or precautions and without restrictions on location and duration of use or body surface area. The FDA is reviewing a supplemental New Drug Application (sNDA) for VTAMA cream as a potential treatment for atopic dermatitis (AD) in adults and children two years of age and older, with Prescription Drug User Fee Act (PDUFA) action expected in the fourth quarter of calendar year 2024.
Plaque psoriasis and atopic dermatitis-commonly known as eczema-are common chronic inflammatory skin diseases affecting millions of people in the U.S. and around the globe.(1) (,) (2) Psoriasis presents a significant impact to quality of life and atopic dermatitis is associated with a higher disease burden for women compared to men.(3) (, ) (4)
"The future of dermatology depends on innovative treatments like VTAMA, and Organon's acquisition of Dermavant allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments," said Kevin Ali, Chief Executive Officer of Organon. "Integrating the expertise of Dermavant into Organon's U.S. organization marks the beginning of a new chapter in dermatology. We are excited to bring this nonbiologic non-steroidal topical option to the millions of patients suffering from a chronic skin condition like plaque psoriasis and, potentially in the future, atopic dermatitis."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
2590 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2537Followers
    107Following
    28KVisitors
    Follow
    More from Jaguar8